Drug RC48 for HER2-low or HER2-ultralow breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests RC48, an antibody-drug treatment, for people with advanced breast cancer that cannot be cured or removed, specifically HER2-low (or HER2-ultralow) tumors. It may help by targeting cancer cells with this “HER2-low” trait while limiting spread in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older
- Your expected survival is at least 12 weeks
- You can do usual activities with little or no help (ECOG 0–1)
- Your breast cancer is confirmed to be advanced/metastatic and cannot be cured or removed
- Your scans show at least one measurable tumor spot
- Your tumor is HER2-low (IHC 1+ or IHC 2+ with a negative FISH test) or HER2-ultralow (tiny, faint incomplete staining in more than 0% but 10% or less)
- You have not previously received an antibody-drug conjugate (like HER2 “ADC” drugs) and you’ve had no more than 1 prior chemotherapy for advanced disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether injecting a targeted drug (RC48) directly into the bladder after surgery for upper urinary tract cancer can help prevent recurrence in patients whose tumors have high levels of a protein called HER2. The drug is designed to attack cancer cells while minimizing harm to healthy cells.
This trial tests two drugs, disitamab vedotin and trastuzumab, for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or come back after at least one prior treatment. The goal is to see if this combination can help shrink tumors.
This trial tests an investigational drug called Disitamab Vedotin for people with advanced Paget's disease that tests positive for HER2. It aims to see if the drug can shrink tumors or improve skin lesions.
This trial studies disitamab vedotin (also called RC48-ADC) in people with breast cancer. It is mainly for patients who have already used this specific drug, to see how well it works as part of the study.
This trial tests two drugs (disitamab vedotin and tislelizumab) designed to treat a type of cancer in the upper urinary tract (kidney and ureter) while preserving kidney function. It's for patients with HER2-positive tumors who want to avoid or cannot have kidney removal surgery.
This trial tests a combination of two drugs (disitamab vedotin and toripalimab) followed by chemotherapy before surgery for people with a specific type of breast cancer that is hormone receptor-positive and HER2-low. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.